Patents Assigned to Biomethodes
-
Patent number: 9903873Abstract: The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker.Type: GrantFiled: April 4, 2006Date of Patent: February 27, 2018Assignee: BIOMETHODESInventor: Marc Delcourt
-
Patent number: 9637728Abstract: The present invention provides T. reesei endoglucanase I variants exhibiting improved cellulase and/or xylanase activity, in particular at 30° C. and/or pH 6. These variants are particularly useful in industrial processes comprising simultaneous degradation of cellulosic biomass into monomeric sugars and fermentation of said sugars, for example to produce ethanol.Type: GrantFiled: July 25, 2014Date of Patent: May 2, 2017Assignee: BIOMETHODESInventors: Stéphane Blesa, Céline Coursange, Bruno Winter
-
Patent number: 9109210Abstract: The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.Type: GrantFiled: July 1, 2010Date of Patent: August 18, 2015Assignee: BIOMETHODESInventors: Stephane Blesa, Helene Chautard, Marc Delcourt, Laurent Mesta, Bruno Winter
-
Patent number: 8623824Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.Type: GrantFiled: February 22, 2008Date of Patent: January 7, 2014Assignees: Biomethodes, Hospices Civils de LyonInventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
-
Publication number: 20130122567Abstract: The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.Type: ApplicationFiled: July 1, 2010Publication date: May 16, 2013Applicant: BIOMETHODESInventors: Stephane Blesa, Helene Chautard, Marc Delcourt, Laurent Mesta, Bruno Winter
-
Publication number: 20100311659Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.Type: ApplicationFiled: February 22, 2008Publication date: December 9, 2010Applicants: BIOMETHODES, HOSPICES CIVILS DE LYONInventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
-
Publication number: 20100260704Abstract: The present invention relates to human interferon gamma variants with improved thermostability, to a nucleic acid encoding said variants, to a pharmaceutical composition containing them, and to their use for the treatment of a viral infection and of cancer.Type: ApplicationFiled: March 8, 2007Publication date: October 14, 2010Applicant: BIOMETHODESInventors: Jose Berenguer, Marc Delcourt, Héléne Chautard, Thierry Menguy
-
Publication number: 20090131264Abstract: The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker.Type: ApplicationFiled: April 4, 2006Publication date: May 21, 2009Applicant: BIOMETHODESInventor: Marc Delcourt
-
Patent number: 7202086Abstract: The invention concerns the field of molecular biology and more particularly that of mutagenesis. It concerns a method of high-rate directed mutagenesis, that is the formation of numerous directed mutants in reduced time and with reduced number of steps. Said method is therefore referred to as massive mutagenesis.Type: GrantFiled: August 24, 2001Date of Patent: April 10, 2007Assignee: BiomethodesInventors: Marc Delcourt, Stephane Blesa
-
Patent number: 6924112Abstract: The present invention pertains to a process for isolating an intact clone of one target nucleic acid fragment having a known characteristic, from a group of fragments by preparing an initial library of clones from the group of fragments using a vector containing no more than a predetermined number of known restriction sites, preferably 1–3 restriction sites, subjecting the initial library to at least 10, and preferably between 50 and 70 restriction enzymes different from those to which the vector is susceptible, to produce a group of monodigested libraries, screening the group of monodigested libraries for the target fragment to determine those restriction enzymes to which the target fragment is insensitive, and subjecting the initial library to substantially all of the restriction enzymes to which the target fragment is insensitive, to produce a multidigested library having an intact clone of the target nucleic acid fragment.Type: GrantFiled: June 2, 2000Date of Patent: August 2, 2005Assignee: Biomethodes S.A.R.L.Inventor: Marc Delcourt
-
Publication number: 20050153343Abstract: The invention relates to the field of molecular biology and more particularly that of mutagenesis. The invention has as its object a method of high throughput directed mutagenesis, that is to say, constitution of a large number of directed mutants at a reduced cost, time and number of steps. The invention also relates to the double stranded polynucleotides so obtained and the peptides, polypeptides, or proteins so obtained having one or more improved properties, and the uses of said method.Type: ApplicationFiled: December 15, 2004Publication date: July 14, 2005Applicant: BIOMETHODESInventors: Julien Sylvestre, Marc Delcourt